Chroma has a broad pipeline addressing all key validated chromatin targets. These targets cover a wide range of discrete disease pathways and are expected to show utility in multiple tumour types. In addition, Chroma is rapidly building a pipeline of novel cancer and inflammation therapies using its proprietary cell accumulation approach.

Click on any of the highlighted programme's for more information on the current status.